Clinical trial results for MCM cytology based assay to be presented at AUA’17, Boston May 12
The ground breaking results of a 275-patient multi-centered UK clinical trial will be presented at this year’s AUA conference, in Boston by Mr. Kasra Saeb-Parsy BSc, MB BS, AFHEA, FRCSEd (Urol), Consultant urologist, Cambridge University Hospitals NHS Foundation Trust
Mr. Saeb-Parsy, one of the PI’s in the study, will be explaining how the MCM assay can achieve a sensitivity of 95.8% and specificity of 91.7% in the gross hematuria clinic and 92.3%/80.3% in the surveillance clinic. MCM is a Minichromosome Maintenance Protein involved with the regulation of cell replication. Healthy cells found in urine do not express MCM, whereas cells expressing MCM are indicative of cancerous cells. Recent developments which further improve the clinical utility, accuracy, and health economic aspects of the assay will be discussed.
The presentation concludes that MCM2 detection has the potential to be the basis for a reliable non-invasive test, for diagnosis of primary and recurrent urinary carcinoma, and may be used to stratify cases where there is no likelihood of disease i.e. zero false negatives, thus avoiding invasive intervention and resulting in quantifiable health economic benefits.
MP15-20: MCM-2 cell based assay is a sensitive and specific test for risk stratification of bladder cancer patients.
Friday, May 12 1:00 PM - 3:00 PM
Location: BCEC: Room 252